- Home
- FINW vs DTIL Comparison
FINW vs DTIL Comparison
Compare FINW & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FINW | DTIL |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.7M | 194.3M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FINW | DTIL |
|---|---|---|
| Price | $13.72 | $7.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 15.5K | ★ 207.2K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.51 | N/A |
| EPS | ★ 1.13 | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | $160.48 | N/A |
| Revenue Next Year | $35.27 | N/A |
| P/E Ratio | $12.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.59 | $3.53 |
| 52 Week High | $22.49 | $8.82 |
Technical Indicators
Market Signals| Indicator | FINW | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 27.82 | 59.17 |
| Support Level | N/A | $4.56 |
| Resistance Level | $18.95 | $7.84 |
| Average True Range (ATR) | 0.67 | 0.50 |
| MACD | -0.29 | -0.05 |
| Stochastic Oscillator | 15.50 | 63.29 |
Price Performance
Historical ComparisonAbout FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and commercial customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).